Kirby McInerney LLP is investigating potential claims against Hospira, Inc. ("Hospira" or the "Company") (NYSE:HSP) concerning the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE:PFE). Under the terms of the definitive merger agreement, Hospira stockholders will receive $90.00 in cash for each share of Hospira common stock they own, valuing the transaction at a total enterprise value of approximately $17 billion. The investigation concerns whether the Hospira Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company's common stock. If you are a Hospira stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at firstname.lastname@example.org, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you. Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.